BioXcel Therapeutics Announces Closing of Initial Public Offering
March 12, 2018 16:01 ET
|
BioXcel Corporation
BRANFORD, Conn., March 12, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics Announces Pricing of Initial Public Offering
March 08, 2018 08:30 ET
|
BioXcel Corporation
BRANFORD, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the...
BioXcel Therapeutics Files Registration Statement for Proposed Initial Public Offering
February 13, 2018 09:15 ET
|
BioXcel Corporation
BRANFORD, Conn., Feb. 13, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the...
New Research Collaboration Between BioXcel Therapeutics and Nektar to Evaluate BXCL701 in Combination with NKTR-214 in Multiple Oncology Indications
November 13, 2017 08:00 ET
|
BioXcel Corporation
BRANFORD, Conn., Nov. 13, 2017 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI”), a biopharmaceutical company committed to developing novel drugs targeting immuno-oncology and neurological and...
BioXcel Therapeutics to Present Data on [BXCL701] at the 24th Annual Prostate Cancer Foundation Scientific Retreat
October 05, 2017 08:00 ET
|
BioXcel Corporation
BRANFORD, Conn., Oct. 05, 2017 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, a biopharmaceutical company committed to developing novel drugs targeting immuno-oncology and neurological and psychiatric...
InveniAI Is Launched with Industry-leading Artificial Intelligence (AI) Powered R&D Engine for Biotech and Pharma Partners
May 16, 2017 08:00 ET
|
BioXcel Corporation
BRANFORD, Conn., May 16, 2017 (GLOBE NEWSWIRE) -- BioXcel Corporation, a privately held biopharmaceutical company pioneering the integration of big data analytics and machine learning-based AI with...
BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in Immuno-oncology and Neuroscience
May 10, 2017 09:00 ET
|
BioXcel Corporation
BRANFORD, Conn., May 10, 2017 (GLOBE NEWSWIRE) -- BioXcel Corporation, a privately held biopharmaceutical company pioneering the integration of big data analytics and machine learning-based...
BioXcel Presents Promising Data Demonstrating BXCL701 / Anti-PD1 Combination Increases Anti-Tumor Cytokines and Tumor Growth Inhibition at 2017 AACR Annual Meeting
April 03, 2017 08:30 ET
|
BioXcel Corporation
BRANFORD, Conn., April 03, 2017 (GLOBE NEWSWIRE) -- BioXcel, a biopharmaceutical company integrating big data analytics and machine learning-based artificial intelligence (AI) with drug development...
UPDATE -- BioXcel Appoints Eric K. Rowinsky, M.D. to its Board of Directors
January 05, 2017 08:14 ET
|
BioXcel Corporation
BRANFORD, Conn., Jan. 05, 2017 (GLOBE NEWSWIRE) -- BioXcel, a privately held biopharmaceutical company pioneering the integration of big data analytics and machine learning-based artificial...
BioXcel Appoints Eric K. Rowinsky, M.D. to its Board of Directors
January 05, 2017 08:00 ET
|
BioXcel Corporation
BRANFORD, Conn., Jan. 05, 2017 (GLOBE NEWSWIRE) -- BioXcel, a privately held biopharmaceutical company pioneering the integration of big data analytics and machine learning-based artificial...